45 8

Full metadata record

DC FieldValueLanguage
dc.contributor.author양철수-
dc.date.accessioned2019-11-22T00:27:29Z-
dc.date.available2019-11-22T00:27:29Z-
dc.date.issued2017-03-
dc.identifier.citationMICROBIAL CELL, v. 4, no. 3, page. 105-107en_US
dc.identifier.issn2311-2638-
dc.identifier.urihttp://microbialcell.com/researcharticles/advancing-host-directed-therapy-for-tuberculosis-new-therapeutic-insights-from-the-toxoplasma-gondii/-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/113354-
dc.description.abstractTuberculosis (TB) drug-development strategies, a wide range of candidate host-directed therapies (HDT) sincluding new and repurposed drugs, biologics, and cellular therapies-have been proposed to accelerate eradication of infection and overcome the problems associated with current treatment regimens. By investigating the interaction between macrophages and the intracellular parasite Toxoplasma gondii (T. gondii), we uncovered that infection-induced signaling pathways suggest possibilities for the development of novel therapeutic modalities for TB that target the intracellular signaling pathways permitting the replication of Mycobacterium tuberculosis (MTB).en_US
dc.description.sponsorshipThis work was supported by the research fund of Hanyang University (HY-2014-N).en_US
dc.language.isoen_USen_US
dc.publisherSHARED SCIENCE PUBLISHERS OGen_US
dc.titleAdvancing host-directed therapy for tuberculosis: new therapeutic insights from the Toxoplasma gondiien_US
dc.typeArticleen_US
dc.relation.no3-
dc.relation.volume4-
dc.identifier.doi10.15698/mic2017.03.565-
dc.relation.page105-107-
dc.relation.journalMicrobial Cell-
dc.contributor.googleauthorYang, Chul-Su-
dc.relation.code2017042716-
dc.sector.campusS-
dc.sector.daehakGRADUATE SCHOOL[S]-
dc.sector.departmentDEPARTMENT OF BIONANOTECHNOLOGY-
dc.identifier.pidchulsuyang-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE